ライフサイエンスコーパス: CpG-ODN

1 CpG ODN enhanced expression of class I MHC and the costi

2 CpG ODN induced early killing of leukemia by innate immu

3 CpG ODN induced expression of CD80 similarly in B cells

4 CpG ODN markedly enhanced the expression and function of

5 CpG ODN treatment of lymphocyte-deficient C57BL/6-scid a

6 CpG ODN trigger immune cells to produce gamma interferon

7 CpG ODN type D were shown to improve clinical outcome in

8 CpG ODN was also co-encapsulated with p-Trp2 as an adjuv

9 CpG ODNs administered to mice efficiently inhibited Th2

10 CpG ODNs did not impair engraftment of TLR9(-/-) BM unle

11 CpG ODNs promoted BM rejection by ligation of donor BM,

12 CpG-ODN attenuation of angiogenesis, however, remains TL

13 CpG-ODN induced a more robust inflammatory response than

14 CpG-ODN pre-treated endothelial cells enhance macrophage

15 CpG-ODN prevented CLP-induced cardiac dysfunction, as ev

16 CpG-ODN prevents CLP-induced cardiac dysfunction, in par

17 CpG-ODN significantly attenuated CLP-induced myocardial

18 CpG-ODN stimulates macrophages and dendritic cells to se

19 CpG-ODN-induced intraocular inflammation was abrogated i

20 CpG-ODNs induced selective IDO expression by a minor pop

21 response against NP in mice immunized with a CpG ODN-containing NP-Ficoll vaccine but exhibited only

22 Here we have identified HMGB1 as a CpG-ODN-binding protein.

23 inhibition of ERK by U0126 in vivo abolished CpG-ODN attenuation of CLP-induced cardiac dysfunction.

24 Additionally, CpG-ODNs induce an M1 macrophage phenotype that restrict

25 y stable hapten analogue and a Th1 adjuvant (CpG ODN).

26 methylated CpG motifs as a vaccine adjuvant (CpG ODN).

27 Addition of the adjuvants CpG-ODN or Poly(I:C) preferentially amplified Teffs over

28 In addition, mice in remission after CpG ODN treatment were protected from leukemia rechallen

29 After CpG-ODN vaccination plus Treg depletion, 70% of young A2

30 By 6 hours after CpG-ODN administration, TLR9 mRNA was increased in the c

31 , or TLR9, but responded to the TLR9 agonist CpG ODN by production of IFNgamma.

32 dendritic cells (PDC) with the TLR9 agonist, CpG ODN 2216, triggered NK lysis of HIV-1-infected autol

33 Despite cell type preferences, all CpG-ODNs require the presence of TLR9 for activation.

34 ml), whereas cells stimulated with Ab alone, CpG ODN alone, or Ab and control ODN produced negligible

35 CpG-DNA or its synthetic analog CpG-ODN activates innate immunity through Toll-like rece

36 B-CLL cells treated with IL-21 and CpG ODN undergo apoptosis and are able to induce apoptos

37 nant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helpe

38 CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-

39 er, co-administration of CpG ODN fma1555 and CpG ODN 1555 in this model increased the window for ther

40 spite a normal response to both anti-IgM and CpG ODN 1826.

41 accinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist had higher frequencies of

42 how that local treatment with Ad5-mTRAIL and CpG ODN can augment tumor antigen cross-presentation res

43 The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce consi

44 nvestigated whether a combination of pFL and CpG ODN as a nasal adjuvant for a pneumococcal surface p

45 tion with PspA plus a combination of pFL and CpG ODN elicited elevated levels of PspA-specific secret

46 ice given PspA plus a combination of pFL and CpG ODN showed protective immunity against nasal S. pneu

47 s of synergy between accessory cytokines and CpG-ODN in NK cells.

48 In contrast, LPS, MPLA, and CpG-ODN, but not poly(I:C), improved the host response t

49 ors was essential for IDO up-regulation, and CpG-ODNs induced selective activation of STAT-1 in CD19+

50 his study, we report the development of anti-CpG-ODN antibodies in 21 of 37 patients who received CpG

51 These data show that topically applied CpG-ODN induces intraocular inflammation owing to TLR9 a

52 e reveal that DEC-205 directly binds class B CpG ODN and enhances their uptake.

53 s identify an important receptor for class B CpG ODN and reveal a unique function for DEC-205.

54 -205 preferentially binds a specific class B CpG ODN that has been selected for human clinical trials

55 of CD11c(hi) DCs from WT, but not T-bet-/-, CpG ODN-treated donor mice.

56 his is the first report of synergism between CpG ODN and IL-2.

57 However, both CpG ODN and imiquimod also induced proinflammatory cytok

58 express both TLR9 and 4, and respond to both CpG ODN and LPS in vitro by differentiating into high af

59 nized CpG-ODN with different CpG motifs, but CpG-ODN with GACGTT or AACGTT had better activity to thi

60 e to infection was significantly enhanced by CpG ODN treatment and was associated with decreased para

61 tigated the antileukemia activity induced by CpG ODN in a transplantable syngeneic pre-B ALL model.

62 ation that is required for CD80 induction by CpG ODN might explain the preservation of this response

63 atal immune system respond to stimulation by CpG ODN, thereby reducing host susceptibility to infecti

64 We show that pDCs activated by CpG-ODN promote NK cell cytotoxicity and interferon (IFN

65 Regulation of angiogenesis by CpG-ODN is pervasive and tissue non-specific.

66 Activation of these two TLRs by CpG-ODN occurred inside the cells and was modulated by U

67 The effects mediated by CpG-ODNs can therefore modulate both endothelial cells a

68 Type C CpG-ODNs combine features of both types A(D) and B(K) Cp

69 Topical or s.c. CpG ODN adjuvant administration at the time of a s.c.

70 The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immun

71 BL/6 mice were treated with CpG-ODN, control CpG-ODN (control-ODN), or inhibitory CpG-ODN (iCpG-ODN)

72 ity of lupus B cells to respond to type A(D) CpG-ODN stimulation is not due to differential TLR9 expr

73 cells from lupus mice responds to type A(D) CpG-ODN stimulation vigorously and directly with increas

74 Therefore, type A(D) CpG-ODNs may contribute to the lupus pathogenesis by ind

75 In mice, type A(D) CpG-ODNs primarily stimulate macrophages and dendritic c

76 R9 expression, but, despite this deficiency, CpG ODNs induce potent inhibitory effects on Th2 cytokin

77 hat, pH-sensitive liposomes co-encapsulating CpG ODN and cGAMP induced synergistic innate immune resp

78 e constitutively active ARF6 mutant enhanced CpG ODN-induced cytokine production.

79 Finally, CpG ODNs may correct deficient newborn response to polys

80 Following CpG-ODN treatment, CD19+ DCs acquired potent IDO-depende

81 sed by a variety of cells, is a receptor for CpG ODN.

82 hat plasmacytoid DCs (pDCs) are required for CpG ODN-mediated protection against lethal vaginal chall

83 the lesions, suggesting a potential role for CpG ODN in L. major treatment.

84 in the spleen express TLR9, the receptor for CpG ODNs, but lung DCs show no detectable expression in

85 a new and alternative signaling pathway for CpG-ODN in murine NK cells.

86 Furthermore, CpG-ODN stimulation in the presence of accessory cytokin

87 l)aminoethyl thiophosphate protecting group (CpG ODN fma1555) was prepared from phosphoramidites 1a-d

88 How CpG ODN are captured and delivered to the intracellular

89 However, CpG ODN delivered with MVA was able to substitute for CD

90 version to the well-studied immunomodulatory CpG ODN 1555 through thermolytic cleavage of the 2-(N-fo

91 ARF6 by dominant mutants and siRNA impaired CpG ODN-mediated responses, whereas cells expressing the

92 The impaired CpG-ODN-induced TNF-alpha production is GNP concentratio

93 n both plasma and peritoneal lavage fluid in CpG ODN-treated versus non-CpG ODN-treated rats 24 h aft

94 nose receptor 1 (MRC1; CD206) is involved in CpG ODN uptake and trafficking in wild-derived MOLF/Ei p

95 yeloperoxidase activity, was also reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CL

96 rial load in peritoneal fluid was reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CL

97 ecruitment of peripheral cells to the CNS in CpG-ODN-inoculated mice.

98 in untreated and IL-4-pretreated but not in CpG-ODN-pretreated cells.

99 olved in opsonin-independent phagocytosis in CpG-ODN-pretreated but not in IL-4-pretreated J774 cells

100 the presence of various adjuvants, including CpG ODN 2006, a synthetic oligonucleotide TLR9 ligand (T

101 rimed with protective TLR ligands, including CpG-ODN, showed reduced plasma cytokines during P. aerug

102 d with CpG ODN but not GpC ODN had increased CpG ODN uptake due to CpG ODN-induced ARF6 activity.

103 control CpG-ODN (control-ODN), or inhibitory CpG-ODN (iCpG-ODN) 1 hour prior to cecal ligation and pu

104 The capacity of prophylactic intranasal CpG ODN to enhance survival does not require adaptive im

105 Fluorescein isothiocyanate-CpG-ODN rapidly penetrated the cornea and ocular media t

106 On the contrary, type B(K) CpG-ODNs are excellent B cell activators.

107 combine features of both types A(D) and B(K) CpG-ODNs.

108 CLPs from mice treated with the TLR9 ligand CpG ODN had little ability to generate CD19+ B lineage c

109 n with TLR7 ligand imiquimod and TLR9 ligand CpG ODN-2216 was also impaired in discordant patients ev

110 ivated by toll-like receptor (TLR)-9 ligand (CpG ODN) stimulation, and both expand and mature after F

111 lylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immu

112 In a different infectious model, CpG ODN 1555 prevented the death of Tacaribe-infected mi

113 herapeutic compounds evaluated in the model, CpG-ODN reduced body weight loss (to <6% on days 3-7 aft

114 ucleotide containing unmethylated CpG motif (CpG-ODN) and alanyl-glutamine in vivo and in vitro.

115 deoxynucleotide (ODN) containing CPG motifs (CpG ODN 7909) was found to protect BALB/c mice from lung

116 oligodeoxynucleotides containing CpG motifs (CpG ODN) enhance allogeneic T(h)1 responses and reduce l

117 ylated cytidyl guanosyl dinucleotide motifs (CpG ODN) are TLR9 ligands with attractive immunostimulat

118 oligodeoxynucleotides containing CpG motifs (CpG ODNs) is remarkably protective against otherwise let

119 s (ODNs) containing unmethylated CpG motifs (CpG ODNs) were shown to activate TLR9-bearing B cells, m

120 In contrast, neither CpG ODN nor LPS alone is sufficient to activate memory B

121 55 in water when compared to that of neutral CpG ODN fma1555 (homologous to 1).

122 Th2-polarizing factors (IL-4, M-CSF, and non-CpG ODN) decreased expression of MARCO on J774 macrophag

123 l lavage fluid in CpG ODN-treated versus non-CpG ODN-treated rats 24 h after CLP.

124 s also reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CLP.

125 id was reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CLP.

126 Both CpG and non-CpG ODNs directly costimulate mouse and human CD4(+) T c

127 ergistic induction of beta-chemokines by non-CpG-ODN was phosphorothioate (PS) chemistry dependent an

128 We have examined combinations of CpG- or non-CpG-ODN and GM-CSF for effects on the production of chem

129 in human primary monocytes when CpG- or non-CpG-ODN was combined with GM-CSF, but not with IL-4 or I

130 DCs is required for the adjuvant activity of CpG ODN in infection, revealing its vital role in innate

131 Addition of CpG ODN increased the CD8(+) response but not the Ab res

132 We found that addition of CpG ODN to modified vaccinia Ankara (MVA) markedly impro

133 further increased 5-fold by the addition of CpG ODN, compared with the levels in mice in the control

134 establish that intranasal administration of CpG ODN 1 day prior to lethal pulmonary exposure to Y. p

135 Moreover, co-administration of CpG ODN fma1555 and CpG ODN 1555 in this model increased

136 Administration of CpG ODN fma1555 three days before infection resulted in

137 Local intradermal administration of CpG ODN fma1555 was as effective as that of CpG ODN 1555

138 human primates showed that administration of CpG ODN type D (also known as type A) at the site of inf

139 Peripheral administration of CpG ODN, both before and after the development of CAA, n

140 amphiphile-CpG, an albumin-binding analog of CpG ODN, following systemic administration 3days after t

141 ting the potential clinical applicability of CpG ODN.

142 This work examines the capacity of CpG ODN to stimulate a protective immune response in new

143 s achieved with much lower concentrations of CpG ODN than optimal induction of proliferation.

144 urrent studies indicate that the delivery of CpG ODN directly into the tumor bed reduces the immunosu

145 D27, indicating that intranasal delivery of CpG ODN has systemic impacts.

146 To further the development of CpG ODN as a novel ALL therapy, we investigated the anti

147 A single dose of CpG ODN was associated with reduced biomarkers of cardia

148 e first time a protective adjuvant effect of CpG ODN for a live viral vector vaccine that may overcom

149 Although the protective effect of CpG ODN in adult mice was well established, its effectiv

150 The effect of CpG ODN is dependent on activation of p38 MAPK.

151 However, the effect of CpG ODN treatment on parasite morphology was not as mark

152 Human NK cells cultured in the presence of CpG ODN plus immobilized IgG or Ab-coated tumor cells se

153 udy, we evaluated the therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, wit

154 The immunostimulatory properties of CpG ODN fma1555 were evaluated in two in vivo assays, on

155 s required for downstream ARF6 regulation of CpG ODN uptake.

156 is the significant increase in solubility of CpG ODN psb1555 and CpG pob1555 in water when compared t

157 orally and spatially controlled targeting of CpG ODN to pDCs and epithelial cells can potentially max

158 CpG ODN fma1555 was as effective as that of CpG ODN 1555 in reducing the size of Leishmania lesions

159 These findings provide new understanding of CpG ODN-mediated antitumor effects and support for the d

160 gnaling by regulating the cellular uptake of CpG ODN.

161 ent of clinical studies to assess the use of CpG ODN types D/A as immunoprotective and therapeutic ag

162 al information for potential clinical use of CpG ODN.

163 Application of CpG ODNs in HIV disease for adjuvant or immunoregulatory

164 Complete conversion of CpG ODNs hbu1555, psb1555, and pob1555 to CpG ODN 1555 (

165 -bet in mediating the protective function of CpG ODNs.

166 ides a molecular basis for the activities of CpG-ODN in fish.

167 vely mediate the antimicrobial activities of CpG-ODN.

168 The combination of CpG-ODN and anti-CCL1 treatments induced complete reject

169 atory indicate that intratumoral delivery of CpG-ODN strongly reduces the levels of Tregs within the

170 that only intratumoral (i.t.) injections of CpG-ODN induce an antitumor response in neu mice.

171 Following intratumoral injections of CpG-ODN, approximately 30% of young A2xneu mice rejected

172 iates the endocytosis and internalization of CpG-ODN by mouse bone marrow-derived macrophages and dir

173 R) 9 and TLR21 are the cellular receptors of CpG-ODN in mammals and chickens, respectively.

174 The ability of CpG-ODNs to induce both stimulatory and regulatory respo

175 findings highlight potential applications of CpG-ODNs and downstream molecules as antiinflammatory ag

176 racellular HMGB1 accelerates the delivery of CpG-ODNs to its receptor, leading to a TLR9-dependent au

177 agents but may complicate therapeutic use of CpG-ODNs to stimulate antitumor immunity in cancer patie

178 CpG oligodeoxynucleotide (CpG ODN) cellular uptake into endosomes, the rate-limiti

179 immunostimulatory CpG oligodeoxynucleotide (CpG ODN) was combined with Ad5-mTRAIL.

180 hylated CpG-containing oligodeoxynucleotide (CpG-ODN) restored IgG anti-PPS14 responses to young adul

181 a CpG motif-containing oligodeoxynucleotide (CpG-ODN), IL-12, and GM-CSF) increased, whereas Th2-pola

182 rly and respond to CpG oligodeoxynucleotide (CpG-ODN) by producing IFN-gamma and GM-CSF.

183 ined the effect of CpG oligodeoxynucleotide (CpG-ODN), the TLR9 ligand, on polymicrobial sepsis-induc

184 R9) stimulation by CpG-oligodeoxynucleotide (CpG-ODN) was integrated into microbiome-gene expression

185 ne-phosphate-guanosine oligodeoxynucleotide (CpG-ODN) to induce neuroinflammation after intracerebrov

186 8) and CpG-containing oligodeoxynucleotides (CpG ODN) to mice, growth of the TRP-2-expressing B16F1 m

187 ligand (pFL) and CpG oligodeoxynucleotides (CpG ODN) as a combined nasal adjuvant elicited mucosal i

188 or a TLR9 ligand [CpG oligodeoxynucleotides (CpG ODN)] had significantly increased Gag-specific T hel

189 e phosphate guanosine oligodeoxynucleotides (CpG ODN), and boosted 12 wk later with a replication-def

190 sine and guanine rich oligodeoxynucleotides (CpG ODN) and their effects on cardiac function, injury,

191 born B lymphocytes to oligodeoxynucleotides (CpG ODN) led to up-regulation of TACI expression on newl

192 CpG-motif containing oligodeoxynucleotides (CpG ODNs) is preceded by agonist endocytosis and deliver

193 PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relaps

194 sphorothioate-guanine oligodeoxynucleotides (CpG ODNs) are synthetic ODNs with unmethylated DNA seque

195 icient in binding CpG oligodeoxynucleotides (CpG-ODN), the microbial DNA mimetic sensed by toll-like

196 e-phosphate-guanosine oligodeoxynucleotides (CpG-ODN), to investigate the role of TLR9 in vascular pa

197 related synthetic CpG oligodeoxynucleotides (CpG-ODNs) play an important role in immune cell survival

198 CpG oligodeoxynucleotides (CpG-ODNs) stimulate innate and adaptive immunity by bind

199 CpG-oligodeoxynucleotides (CpG-ODNs) are potent immune stimuli currently under inve

200 hibition of TLR9 (CpG oligodeoxynucleotides; CpG-ODNs) signal in macrophages.

201 ls with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20(

202 th HIV Gag protein and the TLR7/8 agonist or CpG ODN.

203 djuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalene-based oil-in-water nanoemulsion (N

204 orating GM-CSF in combination with P(I:C) or CpG-ODN induced the complete regression of solid tumors

205 is, we found that pDCs activated by virus or CpG-ODN preferentially express the ligand for the glucoc

206 Vaccine formulations of peptide+CpG-ODN or Poly(I:C) induced selective production of pro

207 Identical TRP-2(180-188) plus CpG ODN vaccines given without IL-2 elicited a TRP-2(180

208 ded systemic IL-2 to the TRP-2(180-188) plus CpG ODN vaccines, growth of B16F1 was inhibited in a CD8

209 When we administered TRP-2(180-188) plus CpG ODN-containing vaccines with systemic IL-2, 18.2% of

210 s when IL-2 was added to TRP-2(180-188) plus CpG ODN-containing vaccines.

211 Peptide plus CpG ODN vaccines administered with IL-2 generated epitop

212 Mice receiving CpG ODN and HER2/neu-positive tumor cells treated with a

213 zebTLR9 broadly recognized CpG-ODN with different CpG motifs, but CpG-ODN with GACG

214 In this regard, CpG ODN show promise as immunoprotective agents and as v

215 Although in the spleen CpG ODNs induced IL-6, a key cytokine induced via TLR9-M

216 were pretreated with vehicle or stimulatory CpG ODN (beating heart control and DCD stimulated with C

217 Surprisingly, certain so-called stimulatory CpG-ODNs strongly inhibited the effector phase of inflam

218 In engraftment studies, CpG ODNs promoted allogeneic donor bone marrow (BM) reje

219 Further, we noted that synthetic CpG-ODN requires backbone phosphorothioate but not TLR9

220 ntibodies cross-reacted with other synthetic CpG-ODNs but not with the DNA of mixed bacterial vaccine

221 animals in a TLR9-dependent manner and that CpG ODN treatment may influence the developmental life c

222 wledge, this is the first demonstration that CpG ODN induce a durable remission and ongoing immune-me

223 These findings indicate that CpG ODN can directly enhance the NK cell cytokine respon

224 in vitro observations, it was observed that CpG ODN could help augment the Ab response against NP in

225 Additional studies showed that CpG ODN uptake was increased in ARF6-activated cells but

226 Further studies showed that CpG ODN-treated microglia increased their capacity to en

227 We show that CpG ODNs markedly accelerated graft-versus-host disease

228 We demonstrate that CpG-ODN stimulates inflammation yet inhibits angiogenesi

229 In vitro experiments demonstrated that CpG-ODN promotes an association between TLR9 and Ras, re

230 Taken together, these results indicate that CpG-ODN-targeted therapy and depletion of T-regs optimal

231 Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBre

232 To identify the gene responsible for the CpG ODN defect, we have performed genome-wide linkage an

233 Several features of the CpG ODN-induced maturation were diminished in monocytes

234 icated as at least a partial mediator of the CpG ODN-induced monocyte maturation.

235 The CpG-ODN binding function of DEC-205 is conserved between

236 Consistent with cytokine inhibition, the CpG-ODN-induced phosphorylation of NF-kappaB and JNK as

237 To target the CpG-ODN to the tumor site anywhere within the body, we c

238 The CpG-ODNs that activate both zebTLR9 and zebTLR21 were mo

239 All of these CpG ODN-mediated impacts, including the increased pulmon

240 Furthermore, these CpG-ODNs induce high surface IgM expression and promote

241 This CpG-ODN chaperone complex-promoted innate immunity confe

242 Even though CpG-ODN injections plus Treg depletion could rescue the

243 TLR9-CpG ODN ligation-induced apoptosis of B-CLL cells is con

244 GpC ODN had increased CpG ODN uptake due to CpG ODN-induced ARF6 activity.

245 R9 allele, R892W, which is hyporesponsive to CpG ODN and acts as a dominant-negative in a cellular mo

246 mouse strain, MOLF/Ei, are hyporesponsive to CpG ODN but are fully responsive to bacterial DNA, thus

247 of CpG ODNs hbu1555, psb1555, and pob1555 to CpG ODN 1555 (homologous to 2) occurred under elevated t

248 tic and stromal compartments must respond to CpG ODN via TLR9 and to type I IFNs through IFN-alphabet

249 Only TLR9-expressing NK cells responded to CpG ODN and Ab, because cytokine production was not obse

250 + NK cells secreted IFN-gamma in response to CpG ODN and Ab-coated tumor cells.

251 duced production of IFN-alpha in response to CpG ODN and reduced frequencies of plasmacytoid dendriti

252 ribute to diminished functional responses to CpG ODN in HIV disease.

253 In contrast, proliferation responses to CpG ODN were markedly impaired in both naive and memory

254 LPS was superior to CpG ODN in increasing the allostimulatory potential of l

255 of TLR signaling pathways was also linked to CpG-ODN responsive fibroblasts, OTU1341 (Prevotella), an

256 ntrast, zebTLR21 responded preferentially to CpG-ODN with GTCGTT motifs.

257 zebrafish TLRs are functional, responding to CpG-ODN but not to other TLR ligands.

258 of proinflammatory cytokines in response to CpG-ODN, although cells from aged mice secreted higher l

259 IL-6, IL-12, TNFalpha, and iNOS response to CpG-ODN.

260 stribution to early endosomes in response to CpG-ODN.

261 o restored corneal inflammatory responses to CpG-ODN.

262 g individuals with fibroblasts responsive to CpG-ODN stimulation.

263 s affected TLR9 translocation in response to CpG-ODNs and to phagosomes.

264 T cell memory can be generated with topical CpG ODN at the time of s.c. immunization, suggesting a n

265 Unlike CpG-ODNs, the effects of GpC-ODN required TLR7/TRIF-medi

266 -dioxygenase (IDO) is induced following i.v. CpG-ODN administration to mice.

267 When CpG ODN are used as an adjuvant, mice deficient in DEC-2

268 caused HMGB1 release into the medium whereas CpG ODN failed to induce this response.

269 ch as IL-15 and IL-18) was required, whereas CpG-ODN or accessory cytokines alone did not induce IFN-

270 nes, reflecting endotoxin tolerance, whereas CpG-ODN-primed mice showed augmented cytokine production

271 irst study assessing the mechanisms by which CpG ODN can protect mice from a neurotropic viral infect

272 vide insight into a novel mechanism by which CpG ODN contribute to tumor regression, and they support

273 ne formulation of (S)MLMH-TT adjuvanted with CpG ODN 1826 + alum successfully raised anti-METH antibo

274 Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to C

275 y of soluble TS recombinant Ag combined with CpG ODN induces both TS-specific CD4(+) and CD8(+) T cel

276 on induced by intranasal TS Ag combined with CpG ODN requires B cells, which, after treatment with Cp

277 8 binding and defective co-localization with CpG ODN.

278 However, only mice with CpG ODN administered topically had significant numbers o

279 BALB/c mice but not TACI knockout mice with CpG ODN containing (4-hydroxy-3-nitrophenyl)acetyl-Ficol

280 Furthermore, cells pretreated with CpG ODN but not GpC ODN had increased CpG ODN uptake due

281 Donor pretreatment with CpG ODN doubled the number of functional DCD hearts at E

282 Indeed, intranasal prophylaxis with CpG ODN provides significant protection against subcutan

283 eating heart control and DCD stimulated with CpG ODN, BST and DST).

284 Plaque tissue stimulation with CpG ODN, a Toll-like receptor (TLR) 9 ligand, increased

285 Newborns treated with CpG ODN are protected from lethal Listeria challenge and

286 Neonatal BALB/c mice treated with CpG ODN at the time of infection had reduced viral load

287 Mice were treated with CpG ODN starting 7 days after injection with leukemia to

288 ination substrate reporter mice treated with CpG ODN.

289 is occurred in TNFalpha-/- mice treated with CpG ODN.

290 equires B cells, which, after treatment with CpG ODN, have the ability to induce TS-specific CD8(+) T

291 ocytogenes infection by prior treatment with CpG ODN.

292 challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection corre

293 Preexposure therapy with CpG ODNs may protect victims of a biological attack from

294 ation and puncture (CLP), and treatment with CpG ODNs reduced sepsis mortality from 80% to 15% during

295 tion of Listeria monocytogenes compared with CpG-ODN treatment alone.

296 nti-Her-2/neu monoclonal antibody (mAb) with CpG-ODN.

297 Male C57BL/6 mice were treated with CpG-ODN, control CpG-ODN (control-ODN), or inhibitory Cp

298 of ongoing and planned clinical trials with CpG-ODNs.

299 Vaccines containing TRP-2(180-188) without CpG ODN did not cause epitope-specific tumor growth inhi

300 Vaccines containing TRP-2(180-188) without CpG ODN elicited TRP-2(180-188)-specific responses of 2.